Bavarian Nordic's IMVANEX® Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
KVISTGAARD, Denmark, May 31, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for IMVANEX® for active immunization against smallpox disease for the general adult population, including people with immunodeficiencies (people diagnosed with HIV or atopic dermatitis).
Help employers find you! Check out all the jobs and post your resume.
KVISTGAARD, Denmark, May 31, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for IMVANEX® for active immunization against smallpox disease for the general adult population, including people with immunodeficiencies (people diagnosed with HIV or atopic dermatitis).
Help employers find you! Check out all the jobs and post your resume.